Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E9.33 EPS (ttm)3.96 Insider Own0.90% Shs Outstand178.00M Perf Week-5.78%
Market Cap6.58B Forward P/E- EPS next Y-1.78 Insider Trans-14.22% Shs Float171.74M Perf Month2.52%
Income745.70M PEG- EPS next Q-0.53 Inst Own94.20% Short Float10.12% Perf Quarter-43.09%
Sales1.25B P/S5.27 EPS this Y188.30% Inst Trans0.01% Short Ratio6.97 Perf Half Y-31.68%
Book/sh10.37 P/B3.57 EPS next Y-145.90% ROA53.60% Target Price81.00 Perf Year-25.56%
Cash/sh7.98 P/C4.64 EPS next 5Y-7.30% ROE78.60% 52W Range33.50 - 111.36 Perf YTD-38.06%
Dividend- P/FCF8.81 EPS past 5Y21.50% ROI56.40% 52W High-67.08% Beta2.87
Dividend %- Quick Ratio13.80 Sales past 5Y30.50% Gross Margin97.90% 52W Low9.43% ATR2.24
Employees509 Current Ratio13.90 Sales Q/Q-81.80% Oper. Margin61.20% RSI (14)39.42 Volatility5.38% 5.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-248.70% Profit Margin59.70% Rel Volume0.71 Prev Close36.99
ShortableYes LT Debt/Eq0.14 EarningsNov 07 AMC Payout0.00% Avg Volume2.49M Price36.66
Recom1.80 SMA20-3.15% SMA50-14.44% SMA200-43.83% Volume1,778,288 Change-0.89%
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Mar-18-15Reiterated Brean Capital Buy $20 → $17
Sep-16-14Reiterated Brean Capital Buy $18 → $20
Dec-10-18 03:40PM  UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
03:08PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm GlobeNewswire
11:18AM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Nektar Therapeutics Investors GlobeNewswire
11:15AM  NKTR REMINDER: Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Dec-09-18 10:23AM  SHAREHOLDER ALERT: DY NKTR GSKY ATUS TX BA APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Dec-07-18 04:23PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
03:14PM  CLASS ACTION UPDATE for IGCC, NKTR, FIT and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
02:17PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, TRVN, GOOG, NKTR and RYAAY GlobeNewswire
11:15AM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Dec-06-18 08:00PM  Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Nektar Therapeutics, Inc. Investors (NKTR) Business Wire
03:00PM  SHAREHOLDER ALERT: JT TRVN HTHT OZK NKTR FIT GSKY ATUS PPDF MAR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
11:55AM  Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
11:43AM  CLASS ACTION UPDATE for TRVN, HTHT and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Dec-05-18 06:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
03:05PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:48PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HTHT, DY, ALGN, NKTR and SYF GlobeNewswire
Dec-04-18 06:41PM  NKTR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics; Important Deadline - NKTR PR Newswire -6.24%
Dec-03-18 03:25PM  SHAREHOLDER ALERT: JT TRVN GOOG CWH OZK NKTR SYF AQUA GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
03:02PM  INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:55AM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, and Honeywell and Encourages Investors to Contact the Firm GlobeNewswire
09:42AM  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics NKTR GlobeNewswire
08:25AM  Report: Exploring Fundamental Drivers Behind CVS Health, TransCanada, Nektar Therapeutics, LendingTree, Spectrum Pharmaceuticals, and TripAdvisor New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-02-18 10:15AM  CLASS ACTION UPDATE for GOOG, OZK, IGCC and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-30-18 05:09PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline  NKTR GlobeNewswire
03:20PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm GlobeNewswire
03:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOOG, OZK, NKTR, FIT and TSRO GlobeNewswire
Nov-29-18 12:09PM  SHAREHOLDER ALERT: ADNT TRVN SFIX GOOG CWH OZK NKTR SYF GSKY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Nov-28-18 08:07PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors Business Wire
03:30PM  CLASS ACTION UPDATE for NKTR, GSKY and RBBN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-27-18 08:10PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Nektar Therapeutics, Inc. Investors (NKTR) Business Wire
01:00PM  Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Nektar Therapeutics (NKTR) and December 31 Lead Plaintiff Deadline PR Newswire
12:25PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:03AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SFIX, GOOG, IGCC, NKTR, SYF and AQUA GlobeNewswire
09:45AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
Nov-26-18 05:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
04:31PM  SHAREHOLDER ALERT: HAS CPB ADNT SFIX GOOG CWH OZK NKTR AQUA RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:16PM  INVESTOR ALERT REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:27AM  Kessler Topaz Meltzer & Check, LLP Reminds Nektar Therapeutics Investors of Important Deadline in Securities Fraud Class Action Lawsuit GlobeNewswire
Nov-25-18 12:03PM  CLASS ACTION UPDATE for JT, OZK and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-23-18 06:15PM  SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline  NKTR GlobeNewswire
11:08AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SFIX, OZK, NKTR, FIT and SYF GlobeNewswire
09:42AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
Nov-21-18 06:01PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
02:20PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics NKTR ACCESSWIRE
11:30AM  SHAREHOLDER ALERT: HAS CPB CHGG ADNT COST SFIX GOOG CWH OZK NKTR AQUA RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Nov-20-18 04:45PM  CLASS ACTION UPDATE for JT, NKTR and AQUA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
04:40PM  NKTR NOTICE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses NKTR Business Wire
12:16PM  Lifshitz & Miller LLP Announces Investigation of Cognizant Technology Solutions Corp., Costco Wholesale Corporation, Datawatch Corporation, Dycom Industries, Inc., India Globalization Capital, Inc., Mercury Systems, Inc., Nektar Therapeutics, and Under Armour, Inc. PR Newswire
12:08PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm Business Wire
Nov-19-18 04:33PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JT, NKTR, SYF and SONS GlobeNewswire
02:08PM  INVESTOR ALERT NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
01:21PM  Kessler Topaz Meltzer & Check, LLP Important Deadline Reminder for Nektar Therapeutics Investors GlobeNewswire
Nov-18-18 10:00AM  SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOOG NKTR SYF RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Nov-16-18 04:56PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline  NKTR GlobeNewswire
10:54AM  CLASS ACTION UPDATE for TRVN, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-14-18 09:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
02:50PM  Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics NKTR ACCESSWIRE
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
09:00AM  Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs PR Newswire
Nov-13-18 12:05PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, JT, COST, CWH, OZK, NKTR and AQUA GlobeNewswire
08:52AM  Nektar (NKTR) Catches Eye: Stock Jumps 8.7% Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-12-18 07:56PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Nektar, and Honeywell and Encourages Investors to Contact the Firm GlobeNewswire +8.73%
05:19PM  SHAREHOLDER ALERT: APOG COCP ABBV COST HTHT SFIX CWH OZK NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
04:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
04:23PM  Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy Investor's Business Daily
09:15AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
09:02AM  Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics GlobeNewswire
08:58AM  INVESTOR NOTICE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Amarin and Nektar Therapeutics ACCESSWIRE
Nov-11-18 10:07AM  CLASS ACTION UPDATE for APOG, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Nov-10-18 09:26PM  Edited Transcript of NKTR earnings conference call or presentation 7-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-09-18 07:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR GlobeNewswire
06:52PM  Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action Business Wire
06:15PM  Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
06:05PM  Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR PR Newswire
02:40PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Nov-08-18 05:55PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COCP, SFIX, CWH, HON, NKTR and SYF GlobeNewswire -6.96%
05:28PM  Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics Business Wire
02:13PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm PR Newswire
01:50PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:11PM  SHAREHOLDER ALERT: MCHP COCP ABBV JT TRVN SFIX CWH HON ALGN NKTR SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:00PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
10:43AM  Nektar (NKTR) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
09:57AM  East Bay biotech scores $42 million with potential quick-fix for heart trouble American City Business Journals
Nov-07-18 09:25PM  Nektar Therapeutics (NKTR) Q3 2018 Earnings Conference Call Transcript Motley Fool +5.18%
06:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR PR Newswire
05:05PM  Nektar: 3Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018 PR Newswire
03:25PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:45PM  CLASS ACTION UPDATE for COCP and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:23AM  Why Nektar Therapeutics Fell 36.5% in October Motley Fool
09:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline: December 31, 2018 ACCESSWIRE
07:18AM  Nektar Therapeutics Q3 Earnings Outlook Benzinga
Nov-06-18 05:38PM  Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Nektar Therapeutics GlobeNewswire -9.80%
05:23PM  Dow Gains 173 Points Because the Market Only Cares That Midterms Are Almost Over Barrons.com
04:45PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, HON, OZK and NKTR GlobeNewswire
04:30PM  Why Nektar Therapeutics Tumbled 10% Today Motley Fool
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM
ROBIN HOWARD WPresident & CEOJun 27Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 27Sale47.3943,3332,053,551224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Sale49.3643,3332,138,917224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Option Exercise10.6943,334463,240267,690Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Sale51.8243,3342,245,568224,356Jun 27 07:42 PM
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale83.393,576298,20365,281May 18 07:07 PM
ROBIN HOWARD WPresident & CEOMay 16Sale83.3912,7911,066,641224,356May 18 07:06 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale83.394,917410,029162,596May 18 07:05 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale83.394,941412,03094,798May 18 07:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale83.394,060338,56376,201May 18 07:02 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale83.393,435286,44563,959May 18 07:01 PM
CHESS ROBERTDirectorMay 03Option Exercise8.7925,000219,700289,223May 04 06:55 PM
ROBIN HOWARD WPresident & CEOMay 03Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Option Exercise10.6930,000320,700129,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 03Sale82.8643,3333,590,572237,147May 03 08:42 PM
CHESS ROBERTDirectorMay 03Sale82.8025,0002,070,050274,223May 04 06:55 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 03Sale82.8630,0002,485,80099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Option Exercise10.6943,333463,230280,480May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 02Sale85.6330,0002,568,90099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 02Sale85.6343,3333,710,605237,147May 03 08:42 PM
ROBIN HOWARD WPresident & CEOMay 01Option Exercise10.6943,334463,240280,481May 03 08:42 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Option Exercise10.6930,000320,700129,739May 03 08:43 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 01Sale83.6530,0002,509,50099,739May 03 08:43 PM
ROBIN HOWARD WPresident & CEOMay 01Sale83.6543,3343,624,889237,147May 03 08:42 PM
WHITFIELD ROY ADirectorApr 17Option Exercise14.2630,000427,800172,000Apr 18 06:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Option Exercise10.6913,881148,38882,738Apr 18 06:03 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerApr 16Sale101.4613,8811,408,36668,857Apr 18 06:03 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Option Exercise7.215023,61980,763Apr 12 06:05 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 10Sale105.6750253,04680,261Apr 12 06:05 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Option Exercise7.2149,500356,895116,894Apr 09 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Option Exercise7.219,49868,48189,759Apr 09 08:22 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 09Sale105.059,498997,76580,261Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 09Sale96.1349,5004,758,43567,394Apr 09 08:21 PM
CHESS ROBERTDirectorApr 06Option Exercise8.7925,000219,700289,223Apr 09 08:20 PM
GREER R SCOTTDirectorApr 06Option Exercise14.2630,000427,800160,333Apr 09 08:22 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Option Exercise9.10110,5001,005,505177,894Apr 09 08:21 PM
Doberstein Stephen KSVP & Chief Scientific OfficerApr 06Sale91.69110,50010,131,74567,394Apr 09 08:21 PM
GREER R SCOTTDirectorApr 06Sale92.2230,0002,766,600130,333Apr 09 08:22 PM
CHESS ROBERTDirectorApr 06Sale92.1425,0002,303,600274,223Apr 09 08:20 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Option Exercise7.2120,000144,200100,261Apr 09 08:22 PM
Lingnau LutzDirectorApr 05Option Exercise9.2430,000277,20057,450Apr 09 08:23 PM
Lingnau LutzDirectorApr 05Sale101.7430,0003,052,20027,450Apr 09 08:23 PM
Hora ManinderSVP Pharma Dev & Mfg OpsApr 05Sale101.7520,0002,035,00080,261Apr 09 08:22 PM
KUEBLER CHRISTOPHER ADirectorMar 07Option Exercise6.2437,400233,23677,900Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 07Sale97.4137,4003,643,13440,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 07Sale100.45100,14410,059,465167,513Mar 08 06:09 PM
KUEBLER CHRISTOPHER ADirectorMar 06Option Exercise5.142,60013,36443,100Mar 08 06:10 PM
KUEBLER CHRISTOPHER ADirectorMar 06Sale100.302,600260,78040,500Mar 08 06:10 PM
Nicholson JohnSVP & Chief Operating OfficerMar 06Sale98.29120,00011,794,800267,657Mar 08 06:09 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale82.942,545211,08268,857Feb 20 07:10 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 16Sale82.944,879404,664387,657Feb 20 07:09 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale82.9412,7881,060,637237,147Feb 20 07:10 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 16Sale82.942,875238,45380,261Feb 20 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 16Sale82.943,477288,38299,739Feb 20 07:08 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 16Sale82.942,426201,21267,394Feb 20 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerJan 31Option Exercise11.34120,0001,360,800392,536Feb 02 06:03 PM
ROBIN HOWARD WPresident & CEOJan 22Option Exercise11.3483,333944,996333,268Jan 24 06:01 PM
ROBIN HOWARD WPresident & CEOJan 22Sale75.8283,3336,318,308249,935Jan 24 06:01 PM
WINGER DENNIS LDirectorJan 04Option Exercise11.9733,750403,98877,000Jan 08 06:07 PM
KUEBLER CHRISTOPHER ADirectorJan 02Option Exercise14.2630,000427,80070,500Jan 04 06:01 PM
KUEBLER CHRISTOPHER ADirectorJan 02Sale58.6630,0001,759,80040,500Jan 04 06:01 PM
ROBIN HOWARD WPresident & CEODec 13Option Exercise11.3483,333944,996272,768Dec 15 06:00 PM
ROBIN HOWARD WPresident & CEODec 13Sale55.6983,3334,640,815189,435Dec 15 06:00 PM